JAMA : the journal of the American Medical Association
-
Comment Meta Analysis
Efficacy and Tolerability of Gefapixant for Treatment of Refractory or Unexplained Chronic Cough: A Systematic Review and Dose-Response Meta-Analysis.
Gefapixant represents an emerging therapy for patients with refractory or unexplained chronic cough. ⋯ Compared with placebo, gefapixant (45 mg orally twice daily) led to modest improvements in cough frequency, cough severity, and cough-specific quality of life but increased taste-related adverse events.
-
Bipolar disorder affects approximately 8 million adults in the US and approximately 40 million individuals worldwide. ⋯ Bipolar disorder affects approximately 8 million adults in the US. First-line therapy includes mood stabilizers, such as lithium, anticonvulsants, such as valproate and lamotrigine, and atypical antipsychotic drugs, such as quetiapine, aripiprazole, asenapine, lurasidone, and cariprazine.